Denis Cavert | Chief Executive Officer
Vaxxel

Denis Cavert, Chief Executive Officer, Vaxxel

Denis R. Cavert is CEO and co-founder of Vaxxel, a Biotech start-up developing intranasal respiratory vaccines against bronchiolitis and viral pneumonia. Vaxxel was created in 2019 with the University of Lyon, France and with the University of Laval, Canada. In vivo Proof of Concept of the first bivalent vaccine candidate against the Metapneumovirus an RSV has been demonstrated.
Denis is also head of DCP Experience a consultancy supporting Biotech and Vaccine companies for Market Access, New product launches, and M&A.
 
He has extensive Biotech and Vaccine industry experience. He has been Director for Strategic Planning and Business Development at Sanofi Pasteur MSD in Europe, Commercila Director of Sanofi Pasteur MSD in Italy, VP Marketing and Sales, Vaccines Europe at Baxter, Bioscience BU director at Baxter France, and Neurology BU Director at Merck Serono France.

Denis holds a Masters in Biotechnology from the National Institute of Applied Sciences (INSA), France, and a Masters in Agro-Food Business Management, ESSEC Business School, France.
He enjoys driving businesses, interacting with teams, and getting results, and likes singing, skiing, Caravaggio, and watching rugby.

Appearances:



Day 2 - Wednesday 30th October @ 15:55

Metavac®-RSV: in vivo Proof of Concept of first Intranasal vaccine against RSV and HMPV

Session led by: vaxxel

Day 2 - Wednesday 30th October @ 15:55

Metavac®-RSV: in vivo Proof of Concept of first Intranasal vaccine against RSV and HMPV

Session led by: vaxxel
last published: 03/Oct/24 13:35 GMT

back to speakers